Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients.
Plasma tetranectin (TN) was tested as a biochemical prognostic marker in ovarian cancer on 39 patients. In stage I + II the 5-year survival was 33% (2/6) if plasma TN was < or = 6.7 mg l-1 and 100% (15/15) with plasma TN > 6.7 mg l-1. For stage III + IV the survival was 0% (0/11) at 26 months for patients with plasma TN < or = 6.7 mg l-1 and 29% (2/7) after 5 years with plasma TN > 6.7 mg l-1. By multivariate testing the relative hazard (RH) of death was found to be 73 times higher in patients with plasma TN < or = 6.7 mg l-1 compared to patients with values above 6.7 mg l-1 (p < 0.001). For comparison, the maximal RH for the other tested variables were: 15 for advanced stage, 2.5 for grade, four for residual tumour and 2.5 for younger age.
Høgdall
C K
CK
Department of Clinical Biochemistry, Statens Seruminstitut, Copenhagen, Denmark.
Høgdall
E V
EV
Hørding
U
U
Clemmensen
I
I
Nørgaard-Pedersen
B
B
Toftager-Larsen
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D037181:Lectins, C-Type; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D015996:Survival Rate
D014408:Biomarkers, Tumor; D001798:Blood Proteins; D037181:Lectins, C-Type; C048648:tetranectin